Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.
复制标题
DOI:
10.1002/cncr.23691
复制
发表时间:
2008-09-15
期刊:
影响因子:
6.2
通讯作者:
Estey, Elihu
中科院分区:
文献类型:
--
作者:
Tsimberidou, Apostolia-Maria;Kantarjian, Hagop M.;Wen, Sijin;Keating, Michael J.;O'Brien, Susan;Brandt, Mark;Pierce, Sherry;Freireieh, Emil J.;Medeiros, L. Jeffrey;Estey, Elihu
It is unknown whether patients with nonleukemic myeloid sarcoma (MS) and those with acute myeloid leukemia (AML) have similar responses to anti-AML treatment. We addressed this question by matching MS patients with analogous AML patients and comparing their clinical outcomes. We identified 23 consecutive MS and 1720 consecutive AML patients who presented at The University of Texas M. D. Anderson Cancer Center from 1990 to 2004. All AML patients and 16 MS patients received cytarabine plus idarubicin or fludarabine as induction remission therapy. We matched treated MS and AML patients according to cytogenetics, age, Zubrod performance status, and time of treatment. Event-free survival (EFS) and overall survival (OS) were compared using Kaplan-Meier analyses. Complete response rates were 69% in MS and 57% in AML (p=0.45). The respective 2-year EFS and OS rates were 32% and 18% (p=0.08) and 43% and 29% (p=0.11). Matches could be found for 14 MS patients, who were paired repeatedly with 91 AML patients to produce 94 matches (3 AML patients were matched twice). EFS was longer in 56 MS pair-mates, shorter in 26, and similar in 12 (p=0.01, Fisher exact test). OS analyses gave similar results. Anti-AML therapy is highly effective in patients with non-leukemic MS. This study emphasizes the need to treat patients with non-leukemic MS with AML-type therapy.
登录
查看更多内容
影响因子:
5.6
作者:
DAVEY, FR;OLSON, S;MASON, DY
通讯作者:
MASON, DY
影响因子:
20.3
作者:
MUSS, HB;MOLONEY, WC
通讯作者:
MOLONEY, WC
影响因子:
11.4
作者:
Tsimberidou, AM;Kantarjian, HM;Giles, FJ
通讯作者:
Giles, FJ
影响因子:
20.3
作者:
Estey, Elihu;de Lima, Marcos;Giralt, Sergio
通讯作者:
Giralt, Sergio
影响因子:
11.4
作者:
Pileri, S. A.;Ascani, S.;Baccarani, M.
通讯作者:
Baccarani, M.